Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

NCT00800683 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: BI 1356
DRUG: placebo

Sponsor

Boehringer Ingelheim